Edition:
United States

Sun Pharma Advanced Research Company Ltd (SPRC.NS)

SPRC.NS on National Stock Exchange of India

398.65INR
18 Aug 2017
Change (% chg)

Rs19.35 (+5.10%)
Prev Close
Rs379.30
Open
Rs378.25
Day's High
Rs403.00
Day's Low
Rs372.45
Volume
1,240,367
Avg. Vol
328,998
52-wk High
Rs403.00
52-wk Low
Rs272.00

Latest Key Developments (Source: Significant Developments)

India's Sun Pharma Advanced Research March-qtr loss widens
Friday, 5 May 2017 05:17am EDT 

May 5 (Reuters) - Sun Pharma Advanced Research Company Ltd :March quarter loss 322.7 million rupees.March quarter total revenue 453.4 million rupees.Says approved allotment of warrants worth inr 5 billion.Net loss in March quarter last year was 95.8 million rupees as per Ind-As; total revenue was 434.9 million rupees.  Full Article

Sun Pharma Advanced Research Co Dec quarter loss widens
Friday, 27 Jan 2017 03:34am EST 

Sun Pharma Advanced Research Company Ltd : Dec quarter net loss 663.3 million rupees . Says accepted resignation of Sudhir Valia as CFO . Dec quarter total income from operations 230.5 million rupees . Says appointed Chetan Rajpara as CFO . Net loss in Dec quarter last year was 410.2 million rupees; total income from operations was 335.5 million rupees .Says Valia to continue as non-executive director.  Full Article

Sun Pharma Advanced Research gets complete response letter from FDA for Xelpros
Wednesday, 21 Dec 2016 10:39pm EST 

Sun Pharma Advanced Research Company Ltd : Update on Xelpros (latanoprost ophthalmic emulsion) NDA . Says co got complete response letter from FDA for Xelpros . Says CRL references recent FDA inspection at Sun Pharma Industries' halol unit . No requirement of additional data from the USFDA on CRL .Says CRL indicates satisfactory resolutions of deficiencies identified during inspection is needed for approval of Xelpros.  Full Article

Sun Pharma Advanced Research posts Sept-qtr profit
Friday, 28 Oct 2016 04:32am EDT 

Sun Pharma Advanced Research Company Ltd : Sept quarter net profit 147.4 million rupees . Sept quarter total income from operations 948.9 million rupees .Net loss in sept quarter last year was 177.4 million rupees; total income from operations was 431.2 million rupees.  Full Article

Sun Pharma Advanced Research June-qtr loss widens
Friday, 29 Jul 2016 05:32am EDT 

Sun Pharma Advanced Research Company Ltd : June-quarter net loss 364.1 million rupees versus loss of 16.5 million rupees last year . June-quarter total income from operations 214.8 million rupees versus 434.4 million rupees last year .  Full Article

Sun Pharma and Almirall signs license deal for Psoriasis treatment
Wednesday, 27 Jul 2016 10:32pm EDT 

Sun Pharmaceutical Industries Ltd : Almirall and Sun Pharma enter into a license agreement for Tildrakizumab in Europe for Psoriasis . To receive development & regulatory milestone payments, royalties, the terms of which are confidential .  Full Article

Almirall signs license deal with Sun Pharma for psoriasis treatment
Wednesday, 27 Jul 2016 11:57am EDT 

Almirall SA : Says enters into a license agreement with Sun Pharma Industries for tildrakizumab in Europe for psoriasis . Says to pay Sun Pharma an initial upfront payment of $50 million . Says Sun Pharma will be eligible to get milestone payments, sales milestone payments and royalties on net sales .Says phase-3 studies of tildrakizumab have recently been completed.  Full Article

Sun Pharma Advanced Research March-qtr net loss widens
Friday, 6 May 2016 06:01am EDT 

Sun Pharma Advanced Research Company Ltd : March quarter net loss 95.8 million rupees versus loss of 94 million rupees . March quarter total income from operations 411.7 million rupees versus 427 million rupees .  Full Article

Sun Pharma Advanced Research Co Ltd Receives Complete Response Letter (CRL) from USFDA for Levetiracetam NDA
Friday, 25 Sep 2015 11:07pm EDT 

Sun Pharma Advanced Research Co Ltd:Announces that the U.S. Food and Drug Administration (USFDA) has issued a Complete Response letter (CRL) to its New Drug Application (NDA) for Elepsia XRTM (Levetiracetam extended-release tablets 1000 mg and 1500 mg).Had earlier received a final approval from USFDA in March 2015 for this product and was evaluating several marketing partners for commercialization.Has now received a CRL from the USFDA rescinding its earlier approval, citing that the compliance status of the manufacturing facility was not acceptable on the date of approval.  Full Article